Press releaseOctober 28 Pharming Group reports financial results for the first nine months of 2021

Pharming Group presents its preliminary (unaudited) financial report for the first nine months ended September 30, 2021.

  • Patient enrollment and product demand driving ongoing revenue recovery to US$52.9 million in Q3 2021
  • Operating profit impacted by upfront payment of US$ 13.1 million for the in-licensing of OTL-105.
  • Continued strong positive cash flow from operations enable increasing investment in the pipeline to support long-term growth

The company will hold an analyst call at 13:30CET/07:30ET today.Details below:

Conference call dial-in information:Thursday October, 28, 2021 13:30CET/07:30ET

Please note, the Company will only take questions from dial-in attendees.

Webcast Link:

https://webcast.openbriefing.com/pharming-q321/

Dial-in details:

Netherlands (Local) 085 888 7233

United Kingdom 0800 640 6441

United Kingdom (Local) 020 3936 2999

United States (Local) 1 646 664 1960

All other locations +44 20 3936 2999

Access code: 147906
Download full press releaseEN
Download volledig persberichtNL

"I look forward to the read-out of the registration enabling study for leniolisib, expected early in the new year, as a product with transformational potential for APDS patient's lives and also transformational commercial potential for Pharming"

- Sijmen de Vries - CEO

Attachments

  • Original document
  • Permalink

Disclaimer

Pharming Group NV published this content on 28 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 October 2021 07:50:04 UTC.